Altimmune (ALT) Cash & Equivalents: 2010-2025
Historic Cash & Equivalents for Altimmune (ALT) over the last 16 years, with Sep 2025 value amounting to $61.3 million.
- Altimmune's Cash & Equivalents rose 94.43% to $61.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.3 million, marking a year-over-year increase of 94.43%. This contributed to the annual value of $37.0 million for FY2024, which is 72.65% down from last year.
- As of Q3 2025, Altimmune's Cash & Equivalents stood at $61.3 million, which was down 66.54% from $183.1 million recorded in Q2 2025.
- Altimmune's Cash & Equivalents' 5-year high stood at $190.3 million during Q4 2021, with a 5-year trough of $31.5 million in Q3 2024.
- Over the past 3 years, Altimmune's median Cash & Equivalents value was $79.0 million (recorded in 2024), while the average stood at $84.3 million.
- In the last 5 years, Altimmune's Cash & Equivalents skyrocketed by 1,226.04% in 2021 and then tumbled by 72.65% in 2024.
- Altimmune's Cash & Equivalents (Quarterly) stood at $190.3 million in 2021, then crashed by 41.61% to $111.1 million in 2022, then climbed by 21.62% to $135.2 million in 2023, then slumped by 72.65% to $37.0 million in 2024, then soared by 94.43% to $61.3 million in 2025.
- Its Cash & Equivalents was $61.3 million in Q3 2025, compared to $183.1 million in Q2 2025 and $49.1 million in Q1 2025.